Dual access catheter enables a 0.014" guidewire to remain in place
while delivering contrast, medication, or a second 0.014" guidewire –
new Torque version builds on Vascular Solutions’ long-standing Twin-Pass
Catheter platform with enhanced torque response and precise angle
alignment into side branch vessels
WAYNE, Pa.--(BUSINESS WIRE)--Mar. 14, 2017--
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical
technologies for critical care and surgery, has announced 510(k)
clearance by the Food and Drug Administration and both U.S. and
international commercial launch of the Twin-Pass Torque Dual Access
Catheter.
Twin-Pass Dual Access Catheters contain both a rapid-exchange (RX) lumen
and an over-the-wire (OTW) lumen. With a 0.014" guidewire deployed
through the RX lumen into the main branch, the OTW lumen can be used for
guidewire exchange, subsequent delivery of a second guidewire into a
side branch, or fluid injection to a desired distal vessel segment.
“The Twin-Pass Torque Catheter builds on Vascular Solutions’ 12-year
legacy with our original Twin-Pass Dual Access Catheter, that has been
gaining in popularity among interventionalists as the number of complex
procedures continues to grow rapidly,” said Chad Kugler, Vice President
of Research & Development of the Vascular Solutions division of
Teleflex. “This newly-launched version is designed for procedures that
call for the delivery of two interventional guidewires from a single
catheter in clinical situations where catheter delivery and torsional
control are paramount. The new version of the Twin-Pass will allow the
physician to achieve precise side-branch access, an important capability
in many complex interventions.”
The Twin-Pass Torque Catheter is intended to access discrete regions of
the coronary and/or peripheral vasculature, to facilitate placement and
exchange of guidewires, and to subselectively infuse/deliver diagnostic
and therapeutic agents.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson
RCI®, LMA®, Pilling®, Rusch®
and Weck® – trusted brands united by a common sense of
purpose.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
Teleflex, the Teleflex logo, Arrow, Deknatel, Hudson RCI, LMA,
Pilling, Rusch, Twin-Pass, and Weck are trademarks or registered
trademarks of Teleflex Incorporated or its affiliates, in the U.S.
and/or other countries.
© 2017 Teleflex Incorporated. All rights reserved. MC-003134
View source version on businesswire.com: http://www.businesswire.com/news/home/20170314005155/en/
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President, Investor Relations
610-948-2836